Further studies with greater length of PET follow-up and replication in other samples are needed to distinguish these possibilities and assess the extent to which measurement of this tau fragment is specific for AD- versus non-AD pathways to cognitive impairment. The gene discussed is MAPT; the disease is Cognitive impairment.